New mpox vaccine recipe tested in 970 adults

NCT ID NCT07199569

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Bavarian Nordic Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 33 times

Summary

This study tests if the MVA-BN mpox vaccine made in a new type of cell works as well as the current version. About 970 healthy adults aged 18 to 49 will receive two doses. Researchers will measure immune response and check for side effects to ensure the new manufacturing method is safe and effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Accellacare - Knoxville

Knoxville, Tennessee, 37938, United States
Accellacare Research of Salisbury

Salisbury, North Carolina, 28144, United States
Accellacare and McFarland Clinic

Ames, Iowa, 50010, United States
Accellacare of Cary - Cary Medical Group

Cary, North Carolina, 27518, United States
Accellacare of Charleston

Mt. Pleasant, South Carolina, 29464, United States
Avacare

Austin, Texas, 78705, United States
Avacare

Fort Worth, Texas, 76135, United States
Johnson County ClinTrials, LLC

Lenexa, Kansas, 66219, United States
Rochester Clinical Research, Inc

Rochester, New York, 14609, United States
Velocity Clinical Research

Suffolk, Virginia, 23435, United States

Conditions

Explore the condition pages connected to this study.

MONKEYPOX (MPOX)